TAXIS研究方案:临床淋巴结阳性乳腺癌定制腋窝手术联合或不联合腋窝淋巴结清扫后放疗的多中心随机III期试验
TAXIS是一项国际多中心III期非劣效随机对照试验,计划纳入1500例临床淋巴结阳性乳腺癌患者,随机接受定制腋窝手术(TAS)后腋窝淋巴结清扫(ALND)加区域淋巴结放疗(排除清扫腋窝),或TAS后区域淋巴结放疗(包括全腋窝)。主要目的是检验TAS联合腋窝放疗在无病生存方面非劣效于ALND。
要点
- 临床淋巴结阳性乳腺癌患者中,TAS联合腋窝放疗可能非劣效于ALND。
- 试验计划随机1500例患者,主要终点为无病生存。
- 若TAS非劣效,可避免手术过度治疗并降低发病率。
核心结论
- TAXIS试验旨在检验TAS联合腋窝放疗在临床淋巴结阳性乳腺癌患者中非劣效于ALND的无病生存。
研究设计与样本
- 国际多中心III期非劣效随机对照试验,涉及4国34个中心,计划随机1500例临床淋巴结阳性乳腺癌患者。
关键数值与推荐
- 试验组:TAS后行ALND及区域淋巴结放疗(排除清扫腋窝);对照组:TAS后行区域淋巴结放疗(包括全腋窝)。
- 所有患者保乳术后接受全乳放疗,乳房切除术后接受胸壁放疗。
临床怎么用
- 若结果支持非劣效,TAS可能成为临床淋巴结阳性乳腺癌的新手术标准,减少手术并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Complete lymph node removal through conventional axillary dissection (ALND) has been standard treatment for breast cancer patients for almost a century. In the 1990s, however, and in parallel with the advent of the sentinel lymph node (SLN) procedure, ALND came under increasing scrutiny due to its association with significant patient morbidity. Several studies have since provided evidence to suggest omission of ALND, often in favor of axillary radiation, in selected clinically node-negative, SLN-positive patients, thus supporting the current trend in clinical practice. Clinically node-positive patients, by contrast, continue to undergo ALND in many cases, if only for the lack of studies re-assessing the indication for ALND in these patients. Hence, there is a need for a clinical trial to evaluate the optimal treatment for clinically node-positive breast cancer patients in terms of surgery and radiotherapy. The TAXIS trial is designed to fill this gap by examining in particular the value of tailored axillary surgery (TAS), a new technique for selectively removing positive lymph nodes. METHODS: In this international, multicenter, phase-III, non-inferiority, randomized controlled trial (RCT), including 34 study sites from four different countries, we plan to randomize 1500 patients to either receive TAS followed by ALND and regional nodal irradiation excluding the dissected axilla, or receive TAS followed by regional nodal irradiation including the full axilla. All patients undergo adjuvant whole-breast irradiation after breast-conserving surgery and chest-wall irradiation after mastectomy. The main objective of the trial is to test the hypothesis that treatment with TAS and axillary radiotherapy is non-inferior to ALND in terms of disease-free survival of clinically node-positive breast cancer patients in the era of effective systemic therapy and extended regional nodal irradiation. The trial was activated on 31 July 2018 and the first patient was randomized on 7 August 2018. DISCUSSION: Designed to test the hypothesis that TAS is non-inferior to ALND in terms of curing patients and preventing recurrences, yet is significantly superior in reducing patient morbidity, this trial may establish a new worldwide treatment standard in breast cancer surgery. If found to be non-inferior to standard treatment, TAS may significantly contribute to reduce morbidity in breast cancer patients by avoiding surgical overtreatment. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03513614. Registered on 1 May 2018. www.kofam.ch , ID: NCT03513614 . Registered on 17 June 2018. EudraCT No.: 2018-000372-14.
引用
- Henke G, Knauer M, Ribi K, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018. PMID: 30514362. doi:10.1186/s13063-018-3021-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。